Cipla joins hands with Novartis Pharma AG to market diabetes drug Galvus in India

Read also: CDSCO Panel allows Cipla to waive requirements for phase 4 study of tocilizumab inj for giant cell arthritis

Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category. Type 2 diabetes stops the body from using insulin properly, which can lead to high levels of blood sugar if not treated.

"Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of INR 268 Cr (IQVIA MAT February 2023)," Cipla further informed.

Medical Dialogues team had earlier reported that Medicines Patent Pool (MPP) had signed sublicence agreements with Aurobindo, Cipla and Viatris – through its subsidiary Mylan – to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP).

Read also: Cipla, Aurobindo, Viatris in licensing pact with MPP to produce generic versions of ViiV Healthcare HIV drug

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.

The company specializes in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla's 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to 86 markets. 

Read also: Cipla to sell 51 percent stake in Uganda arm for USD 25-30 million